Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Nucleic Acids Research

• Publication date

  2003-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/NAR/GKG737PMID 14500835PMCID PMC206448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Two-drug Model for Etoposide Action against Human Topoisomerase IIα*

  2003cited by this paper
• ATPase Domain of Eukaryotic DNA Topoisomerase II INHIBITION OF ATPase ACTIVITY BY THE ANTI-CANCER DRUG BISDIOXOPIPERAZINE AND ATP/ADP-INDUCED DIMERIZATION*

  2002cited by this paper
• ATPase Domain of Eukaryotic DNA Topoisomerase II

  2002cited by this paper
• Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA.

  2001cited by this paper
• ATP-bound Topoisomerase II as a Target for Antitumor Drugs*

  2001cited by this paper
• Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.

  2000cited by this paper
• A Mutation in Yeast Topoisomerase II That Confers Hypersensitivity to Multiple Classes of Topoisomerase II Poisons*

  2000cited by this paper
• Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance

  2000cited by this paper
• A truncated cytoplasmic topoisomerase IIα in a drug‐resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34

  2000cited by this paper
• Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.

  2000cited by this paper
• Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.

  1999cited by this paper
• Mutation of a Conserved Serine Residue in a Quinolone-resistant Type II Topoisomerase Alters the Enzyme-DNA and Drug Interactions*

  1999cited by this paper
• Analysis of nuclear organization in Saccharomyces cerevisiae.

  1999cited by this paper
• Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.

  1998cited by this paper
• A Mutant Yeast Topoisomerase II (top2G437S) with Differential Sensitivity to Anticancer Drugs in the Presence and Absence of ATP*

  1998cited by this paper
• Investigating the biological functions of DNA topoisomerases in eukaryotic cells.

  1998cited by this paper
• Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.

  1998cited by this paper
• Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.

  1998cited by this paper
• Analysis of a Core Domain in Drosophila DNA Topoisomerase II

  1998influential reference
• Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.

  1997cited by this paper
• Cancer Therapeutics: Experimental And Clinical Agents

  1997cited by this paper
• Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae

  1996cited by this paper
• Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.

  1996cited by this paper
• Antitopoisomerase drug action and resistance.

  1996cited by this paper
• The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X‐ray crystallography.

  1996influential reference
• Topoisomerase II·Etoposide Interactions Direct the Formation of Drug-induced Enzyme-DNA Cleavage Complexes*

  1996cited by this paper
• Analysis of Functional Domain Organization in DNA Topoisomerase II from Humans and Saccharomyces cerevisiae

  1996cited by this paper
• DNA topoisomerase II mutations and resistance to anti‐tumor drugs

  1995cited by this paper
• Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA.

  1995cited by this paper
• Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.

  1994cited by this paper
• Structure and function of type II DNA topoisomerases.

  1994cited by this paper
• A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.

  1994cited by this paper
• Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

  1994cited by this paper
• When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs.

  1993cited by this paper
• Drug resistance associated with altered DNA topoisomerase II.

  1993cited by this paper
• On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II.

  1993cited by this paper
• Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.

  1992cited by this paper
• Localization of RAP1 and topoisomerase II in nuclei and meiotic chromosomes of yeast

  1992cited by this paper
• Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.

  1991cited by this paper
• Topoisomerase-targeting antitumor drugs.

  1989cited by this paper

• Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586

  2025cites this paper
• 1,2-Naphthoquinone as a Poison of Human Type II Topoisomerases.

  2021cites this paper
• One-pot synthesis of thiazolo[3,2-a]pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies.

  2020cites this paper
• The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase IIα (TOP2α/90) Is a Determinant of Etoposide Resistance in K562 Leukemia Cells via Heterodimerization with the TOP2α/170 Isoform

  2018cites this paper
• A non-canonical JAGGED1 signal to JAK2 mediates osteoblast commitment in cranial neural crest cells

  2018cites this paper
• The rational targeting of the DNA damage response pathway for the selective elimination of encephalitogenic T cells

  2015cites this paper
• Design and docking of novel series of hybrid xanthones as anti- cancer agent to target human DNA topoisomerase 2-alpha

  2014cites this paper
• Treatment with Gefitinib or Lapatinib Induces Drug Resistance through Downregulation of Topoisomerase IIα Expression

  2013cites this paper
• DOWNREGULATION OF TOPOISOMERASE IIα EXPRESSION

  2013cites this paper
• Modulation of DNA strand break induction and repair bytyrosine kinase inhibitors targeted against EGFR and HER2

  2012cites this paper
• DNA topoisomerases of Leishmania: the potential targets for anti-leishmanial therapy.

  2008cites this paper
• Single molecule transcription profiling with AFM

  2007cites this paper
• Cellular response to etoposide treatment.

  2007cites this paper
• Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain

  2007cites this paper
• Use of Serial Analysis of Gene Expression (Sage) for Transcript Profiling in Plants

  2007cites this paper
• Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides

  2006cites this paper
• Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.

  2005cites this paper
• Novel carbamate derivatives of 4-beta-amino-4'-O-demethyl-4-desoxypodophyllotoxin as inhibitors of topoisomerase II: synthesis and biological evaluation.

  2005cites this paper
• Current awareness on yeast

  2004cites this paper
• Critical structural motif for the catalytic inhibition of human topoisomerase II by UK-1 and analogs.

  2004cites this paper